Enanta Pharmaceuticals vs Tango Therapeutics
Enanta Pharmaceuticals reported revenue of $63 million in fiscal 2026, about the same as Tango Therapeutics' $62 million in fiscal 2025. Enanta Pharmaceuticals' revenue fell 3.6% in its latest year, and Tango Therapeutics' grew 48.3%. Enanta Pharmaceuticals had an operating margin of -99.0%, against -178.4% at Tango Therapeutics. Free cash flow was −$43 million at Enanta Pharmaceuticals and −$140 million at Tango Therapeutics. Their fiscal years end in different months (September 30 and December 31), so the periods don't line up exactly.
Side by side
| Enanta Pharmaceuticals | Tango Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2026, Sep 30, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $63M | $62M |
| Revenue growth | −3.6% | 48.3% |
| Revenue growth a year, last 5 years | −8.3% | 52.0% |
| Gross margin | — | — |
| Operating margin | −99.0% | −178.4% |
| Net margin | −108.3% | −162.8% |
| Free cash flow | −$43M | −$140M |
| Free cash flow margin | −67.9% | −224.3% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 35.9% | 6.3% |
| Last close | $7.98 | $22.71 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $183,168 | sold $7.2 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Enanta PharmaceuticalsTango Therapeutics
Operating margin
Percent of revenue
Enanta PharmaceuticalsTango Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Enanta PharmaceuticalsTango Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Enanta Pharmaceuticals and Tango Therapeutics pages.